Passer au français
Elmiron Eye Damage (Maculopathy) Canadian Class Action
-
ON May 19, 2020 [en]
U.S. Personal Injury Compaint 2 -
ON May 06, 2020 [en]
U.S. Class Action Complaint -
QC Mar 26, 2020 [en]
U.S. Personal Injury Compaint 1 -
QC Sep 28, 2019 [fr]
Monographie de produit -
QC Sep 23, 2019 [en]
Product Monograph - Health Canada
CONSUMER LAW GROUP is investigating a Canada-wide class action lawsuit against Janssen and IVAX Research, LLC for the side-effect of their drug Elmiron (pentosan polysulfate sodium), which can cause an eye disorder called maculopathy (a progressive disease that can lead to vision loss, usually in both eyes) in some patients.
The lawsuit is based on the allegation that the makers of Elmiron failed to properly warn the public about the risk of irreversible vision damage.
Elmiron is an oral prescription drug used to treat discomfort or bladder pain associated with interstitial cystitis, a chronic condition that causes bladder pain and pressure.
Over time, more and more studies have revealed the link between Elmiron and maculopathy:
• In November 2018, the medical journal Ophthalmology published an article entitled Pigmentary Maculopathy Associated With Chronic Exposure to Pentosan Polysulfate Sodium whereby it was found that chronic exposure to the drug caused unique pigmentary maculopathy - specifically, injury to the retinal pigment epithelium, a layer of cells that nourishes the retina.
• In April 2019, the Journal of Urology published an article entitled Chronic Exposure to Pentosan Polysulfate Sodium is Associated with Retinal Pigmentary Changes and Vision Loss whereby it was found that patients with a history of IC who did not take pentosan polysulfate sodium did not have the unique form of pigmented maculopathy present in patients who took the drug.
• In October 2019, the medical journal Ophthalmic Surgery, Lasers and Imaging Retina published an article entitled Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium whereby it was found that the toxicity was greater in patients who took more of the drug.
• In November 2019, the British Journal of Ophthalmology published an article entitled Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort whereby it was found that pentosan users had significantly increased odds of macular disease at 7 years.
• In February 2020, the Canadian Urological Association Journal published an article entitled Possible Drug-Induced, Vision-Threatening Maculopathy Secondary to Chronic Pentosan Polysulfate Sodium (Elmiron®) Exposure whereby it was found that pentosan users had significantly increased odds of macular disease at 7 years.
If you or someone you know has taken Elmiron and suffered eye injury and you wish more information on potential compensation or to be kept advised of the status of the Elmiron Eye Damage (Maculopathy) Canadian Class Action or any resulting compensation thereof in Canada, Ontario or Quebec, please provide your contact information to our law firm using the form below.
IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.
